Jasper shares decline following trial setback from faulty drug batch
Jasper is halting the development of briquilimab in asthma and SCID.
08 July 2025
08 July 2025
Jasper is halting the development of briquilimab in asthma and SCID.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.